Non-small cell lung cancer with BRAF mutation treated with neoadjuvant targeted therapy followed by surgery: A case report_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

NING Yingze ¹ , LIN Chutong ¹ , ZHU Xiang ² ,  QIANG Guangliang ¹

1. Department of Thoracic Surgery, Peking University Third Hospital, Beijing, 100191, P. R. China;
2. Department of Pathology, Peking University Third Hospital, Beijing, 100191, P. R. China;

Corresponding author：

QIANG Guangliang, Email: pkudd@126.com

Keywords：

Non-small cell lung cancer; BRAF mutation; neoadjuvant therapy; targeted therapy

DOI：

10.7507/1007-4848.202407077

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

This study reports a case of a 56-year-old female patient with BRAF-mutated non-small cell lung cancer (NSCLC) who successfully underwent curative surgery after neoadjuvant targeted therapy with the BRAF inhibitor dabrafenib combined with the MEK inhibitor trametinib. The chest drainage tube was removed 2 days postoperatively, and the patient was discharged smoothly. Postoperative pathology indicated invasive adenocarcinoma, moderately to highly differentiated, with 80% being lepidic type, and the maximum tumor diameter was 4 cm. No vascular invasion, nerve invasion, air cavity dissemination, pleural invasion, or lymph node metastasis were observed. The postoperative staging was ypT2aN0M0. The patient continued with adjuvant treatment with dabrafenib combined with trametinib postoperatively, and no signs of recurrence were found in the follow-up examination six months after surgery.

1.	Mazieres J, Cropet C, Montané L, et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol, 2020, 31(2): 289-294.
2.	Lin Q, Zhang H, Ding H, et al. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. J Transl Med, 2019, 17(1): 298.
3.	Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol, 2011, 29(26): 3574-3579.
4.	Mu Y, Yang K, Hao X, et al. Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer. Front Oncol, 2020, 10: 603.
5.	Zhang C, Zhang C, Lin J, et al. Patients with BRAF-mutant NSCLC may not benefit from immune checkpoint inhibitors: A population-based study. JTO Clin Res Rep, 2020, 1(1): 100006.
6.	Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol, 2017, 18(10): 1307-1316.
7.	Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid, 2019, 29(8): 1036-1043.
8.	Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stageⅢ melanoma. N Engl J Med, 2020, 383(12): 1139-1148.
9.	Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med, 2019, 381(7): 626-636.
10.	Garassino MC, Oskar S, Arunachalam A, et al. Real-world treatment patterns and outcomes of first-line immunotherapy among patients with advanced nonsquamous NSCLC harboring BRAF, MET, or HER2 alterations. JTO Clin Res Rep, 2023, 4(10): 100568.

1. Mazieres J, Cropet C, Montané L, et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol, 2020, 31(2): 289-294.
2. Lin Q, Zhang H, Ding H, et al. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. J Transl Med, 2019, 17(1): 298.
3. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol, 2011, 29(26): 3574-3579.
4. Mu Y, Yang K, Hao X, et al. Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer. Front Oncol, 2020, 10: 603.
5. Zhang C, Zhang C, Lin J, et al. Patients with BRAF-mutant NSCLC may not benefit from immune checkpoint inhibitors: A population-based study. JTO Clin Res Rep, 2020, 1(1): 100006.
6. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol, 2017, 18(10): 1307-1316.
7. Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid, 2019, 29(8): 1036-1043.
8. Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stageⅢ melanoma. N Engl J Med, 2020, 383(12): 1139-1148.
9. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med, 2019, 381(7): 626-636.
10. Garassino MC, Oskar S, Arunachalam A, et al. Real-world treatment patterns and outcomes of first-line immunotherapy among patients with advanced nonsquamous NSCLC harboring BRAF, MET, or HER2 alterations. JTO Clin Res Rep, 2023, 4(10): 100568.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Latest ArticlesNon-small cell lung cancer with BRAF mutation treated with neoadjuvant targeted therapy followed by surgery: A case report

Abstract Full text Figures/Tables Video References Cited by

Format

Content